Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers

(2016) G. Karpel-Massler et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer

(2016) O. Clark et al.   CLINICAL CANCER RESEARCH

Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo

(2016) Georg Karpel-Massler et al.   Oncotarget

Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo

(2016) Georg Karpel-Massler et al.   Oncotarget

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion

(2015) Kensuke Tateishi et al.   CANCER CELL

2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling

(2015) Xudong Fu et al.   Cell Metabolism

Adaptive Mitochondrial Reprogramming and Resistance to PI3K Therapy

(2015) Jagadish C. Ghosh et al.   JNCI-Journal of the National Cancer Institute

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia

(2015) Ujunwa C Okoye-Okafor et al.   Nature Chemical Biology

Integrated genomic characterization of IDH1-mutant glioma malignant progression

(2015) Hanwen Bai et al.   NATURE GENETICS

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

(2015) Steven M Chan et al.   NATURE MEDICINE

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo

(2015) Georg Karpel-Massler et al.   Oncotarget

Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents

(2015) Pu Wang et al.   Cell Reports

Adaptive Mitochondrial Reprogramming and Resistance to PI3K Therapy

(2015) Jagadish C. Ghosh et al.   JNCI-Journal of the National Cancer Institute

The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells

(2014) Yinxing Liu et al.   ACTA NEUROPATHOLOGICA

Artesunate Enhances the Antiproliferative Effect of Temozolomide on U87MG and A172 Glioblastoma Cell Lines

(2014) Georg Karpel-Massler et al.   Anti-Cancer Agents in Medicinal Chemistry

Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide’s antiproliferative effect

(2014) Georg Karpel-Massler et al.   JOURNAL OF NEURO-ONCOLOGY

PI3K and Bcl-2 Inhibition Primes Glioblastoma Cells to Apoptosis through Downregulation of Mcl-1 and Phospho-BAD

(2014) Fresia Pareja et al.   MOLECULAR CANCER RESEARCH

A vaccine targeting mutant IDH1 induces antitumour immunity

(2014) Theresa Schumacher et al.   NATURE

PARP Inhibition Restores Extrinsic Apoptotic Sensitivity in Glioblastoma

(2014) Georg Karpel-Massler et al.   PLoS One

What do we know about IDH1/2 mutations so far, and how do we use it?

(2013) Craig Horbinski   ACTA NEUROPATHOLOGICA

Autophagy and oxidative stress in gliomas with IDH1 mutations

(2013) Misty R. Gilbert et al.   ACTA NEUROPATHOLOGICA

Murine cell line model of proneural glioma for evaluation of anti-tumor therapies

(2013) Adam M. Sonabend et al.   JOURNAL OF NEURO-ONCOLOGY

Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells

(2013) G. Karpel-Massler et al.   MOLECULAR CANCER THERAPEUTICS

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

(2013) D. Rohle et al.   SCIENCE

mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1

(2013) A. C. Faber et al.   Cancer Discovery

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation

(2012) Sichen Li et al.   NEURO-ONCOLOGY

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells

(2011) Markus D. Siegelin et al.   JOURNAL OF CLINICAL INVESTIGATION

Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1

(2010) M. J. Seltzer et al.   CANCER RESEARCH

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

(2010) Stefan Gross et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

(2009) Martin Schwickart et al.   NATURE

SUnSET, a nonradioactive method to monitor protein synthesis

(2009) Enrico K Schmidt et al.   NATURE METHODS